Nutanix (NTNX) PT Lowered to $28 at Susquehanna; Reiterates Neutral

Needham and Company Maintains Buy Rating and $36 PT on Nutanix (NTNX) Following 'Record' F2Q Results, 'Lower Guidance'

Needham & Company analyst Richard Kugele reiterates Buy rating and $36 price target on Nutanix (NASDAQ: NTNX), noting challenges due to sales changes, as the company reported record fiscal second quarter results, despite lower guidance.

Kugele comments, "It's easy for investors and the... More

Morgan Stanley Downgrades Nutanix (NTNX) to Equalweight

Morgan Stanley downgraded Nutanix (NASDAQ: NTNX) from Overweight to Equalweight with a price target of $20.00 (from $29.00).

Analyst Katy Huberty believes NTNX will require multiple quarters to address and manage headwinds.

"We see four reasons the stock is more likely to trade... More

After-Hours Stock Movers 03/02: (HABT) (VTTI) (GWRE) Higher; (SCYX) (IMMR) (KPTI) Lower (more...)

Today's After-Hours Movers:

SCYNEXIS, Inc. (Nasdaq: SCYX) 30% LOWER; announced that the United States Food and Drug Administration (FDA) has informed the Company to hold the initiation of any new clinical studies with the intravenous (IV) formulation of SCY-078 until the FDA completes a review of all available pre-clinical and clinical data of the IV formulation of SCY-078. Ongoing and future trials using the oral formulation of SCY-078 are unaffected by this regulatory action. A meeting with the FDA to discuss these data and to agree on... More

Nutanix (NTNX) Misses Q2 EPS by 31c

Nutanix (NASDAQ: NTNX) reported Q2 EPS of ($0.66), $0.31 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $182.2 million versus the consensus estimate of $178.38 million.

GUIDANCE:

Nutanix sees Q3 2017 EPS of ($0.48)-($0.45), versus the consensus of ($0.35). Nutanix sees Q3... More